Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical
In the assessment of 12-month price targets, analysts unveil insights for Collegium Pharmaceutical, presenting an average target of $45.5, a high estimate of $50.00, and a low estimate of $36.00.
Q2 EPS Forecast for Corcept Therapeutics Raised by Analyst
Analysts at Zacks Research boosted their Q2 2025 EPS estimates for Corcept Therapeutics in a report released on Wednesday, March 19th. Zacks Research analyst K. Das now forecasts that the ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors
This was the stock's fourth consecutive day of losses.
CWEB3d
Comparative Analysis of Pharmaceutical Companies: OptiNose, Collegium Pharmaceutical, Alkermes, and Deciphera Pharmaceuticals
OptiNose, Inc. (NASDAQ:OPTN) faces a pessimistic outlook from investment analysts with a target price significantly lower than its market price. Collegium Pharmaceutical, Inc. (COLL) is perceived as ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a two-day winning streak.
HC Wainwright Has Bullish Forecast for CRBP Q1 Earnings
Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March ...